000132797 001__ 132797
000132797 005__ 20240229105032.0
000132797 0247_ $$2doi$$a10.1371/journal.pone.0193946
000132797 0247_ $$2pmid$$apmid:29596475
000132797 0247_ $$2pmc$$apmc:PMC5875773
000132797 0247_ $$2altmetric$$aaltmetric:40678678
000132797 037__ $$aDKFZ-2018-00441
000132797 041__ $$aeng
000132797 082__ $$a500
000132797 1001_ $$00000-0002-4319-0428$$aDeike-Hofmann, Katerina$$b0$$eFirst author
000132797 245__ $$aSensitivity of different MRI sequences in the early detection of melanoma brain metastases.
000132797 260__ $$aLawrence, Kan.$$bPLoS$$c2018
000132797 3367_ $$2DRIVER$$aarticle
000132797 3367_ $$2DataCite$$aOutput Types/Journal article
000132797 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1525765933_9525
000132797 3367_ $$2BibTeX$$aARTICLE
000132797 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000132797 3367_ $$00$$2EndNote$$aJournal Article
000132797 520__ $$aAfter the emergence of new MRI techniques such as susceptibility- and diffusion-weighted imaging (SWI and DWI) and because of specific imaging characteristics of melanoma brain metastases (MBM), it is unclear which MRI sequences are most beneficial for detection of MBM. This study was performed to investigate the sensitivity of six clinical MRI sequences in the early detection of MBM.Medical records of all melanoma patients referred to our center between November 2005 and December 2016 were reviewed for presence of MBM. Analysis encompassed six MRI sequences at the time of initial diagnosis of first or new MBM, including non-enhanced T1-weighted (T1w), contrast-enhanced T1w (ceT1w), T2-weighted (T2w), T2w-FLAIR, susceptibility-weighted (SWI) and diffusion-weighted (DWI) MRI. Each lesion was rated with respect to its conspicuity (score from 0-not detectable to 3-clearly visible).Of 1210 patients, 217 with MBM were included in the analysis and up to 5 lesions per patient were evaluated. A total of 720 metastases were assessed and all six sequences were available for 425 MBM. Sensitivity (conspicuity ≥2) was 99.7% for ceT1w, 77.0% for FLAIR, 64.7% for SWI, 61.0% for T2w, 56.7% for T1w, and 48.4% for DWI. Thirty-one (7.3%) of 425 lesions were only detectable by ceT1w but no other sequence.Contrast-enhanced T1-weighting is more sensitive than all other sequences for detection of MBM. Disruption of the blood-brain-barrier is consistently an earlier sign in MBM than perifocal edema, signal loss on SWI or diffusion restriction.
000132797 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000132797 588__ $$aDataset connected to CrossRef, PubMed,
000132797 7001_ $$0P:(DE-He78)09e42570f3a0f020969f90de2e3e7643$$aThünemann, Daniel$$b1$$udkfz
000132797 7001_ $$0P:(DE-He78)5ba5b48bd126214d9cb66291fa4ae303$$aBreckwoldt, Michael$$b2$$udkfz
000132797 7001_ $$0P:(DE-He78)a46ef05266eafb5f42c207880f97ebf6$$aSchwarz, Daniel$$b3$$udkfz
000132797 7001_ $$0P:(DE-He78)77588f5b9413339755a66e739d316c7d$$aRadbruch, Alexander$$b4$$udkfz
000132797 7001_ $$aEnk, Alexander$$b5
000132797 7001_ $$aBendszus, Martin$$b6
000132797 7001_ $$aHassel, Jessica$$b7
000132797 7001_ $$0P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aSchlemmer, Heinz-Peter$$b8$$udkfz
000132797 7001_ $$00000-0003-2896-543X$$aBäumer, Philipp$$b9$$eLast author
000132797 773__ $$0PERI:(DE-600)2267670-3$$a10.1371/journal.pone.0193946$$gVol. 13, no. 3, p. e0193946 -$$n3$$pe0193946 -$$tPLoS one$$v13$$x1932-6203$$y2018
000132797 909CO $$ooai:inrepo02.dkfz.de:132797$$pVDB
000132797 9101_ $$0I:(DE-588b)2036810-0$$60000-0002-4319-0428$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000132797 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)09e42570f3a0f020969f90de2e3e7643$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000132797 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ba5b48bd126214d9cb66291fa4ae303$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000132797 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a46ef05266eafb5f42c207880f97ebf6$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000132797 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)77588f5b9413339755a66e739d316c7d$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000132797 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000132797 9101_ $$0I:(DE-588b)2036810-0$$60000-0003-2896-543X$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000132797 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000132797 9141_ $$y2018
000132797 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPLOS ONE : 2015
000132797 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000132797 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000132797 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000132797 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000132797 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000132797 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000132797 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000132797 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000132797 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000132797 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000132797 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000132797 915__ $$0StatID:(DE-HGF)1040$$2StatID$$aDBCoverage$$bZoological Record
000132797 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000132797 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000132797 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lRadiologie$$x0
000132797 9201_ $$0I:(DE-He78)E012-20160331$$kE012$$lNeuroonkologische Bildgebung$$x1
000132797 980__ $$ajournal
000132797 980__ $$aVDB
000132797 980__ $$aI:(DE-He78)E010-20160331
000132797 980__ $$aI:(DE-He78)E012-20160331
000132797 980__ $$aUNRESTRICTED